Is CareDx, Inc (CDNA) a Buy, Sell, or Hold?
NASDAQ : CDNA
CareDx, Inc
$45.5 USD
-$1.59 (-3.38%)
- Volume
- 1.1M
- Average Volume
- 908.85K
- Market Capitalization
- $2.35B
- P/E Ratio
- 21.14
- Dividend Yield
- 0.00%
- Price Target
- $46.00
- Year High
- $49.76
- Year Low
- $11.26
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.58
Company Overview
NASDAQ
John Walter Hanna Jr.
Medical - Diagnostics & Research
Healthcare
CDNA
765
US
USD
Liquidity Metrics
0.05
4.58
4.51
3.99
0.00
Sales & Valuation
$379.8M
5.14
5.50
27.68
1.65
Profitability
-$0.4
-$21.35M
24.23%
25.15%
32.81%
20.83%
P/E Metrics
21.14
-0.02
-0.02
Analyst Price Target & Rating
$46.00
$64.00
$45.00
4/5
13 Analysts
-1.09%
Financial Health Scores
13.87
7/9
$335.52M
$532.99M
$107.39M
-$4.23M
Key Metrics (TTM)
$2.08B
4.54
133.81
4.58
32.81%
-0.92%
4.58%
3.49%
$20.03
21 days
Company Executives
| Name | Title |
|---|---|
| Jeffrey A. Novack | General Counsel & Secretary |
| Kashif Rathore | Chief Technology Officer |
| Keith S. Kennedy | CFO & COO |
| Jing Huang | Chief Data & Artificial Intelligence Officer |
| Marica Grskovic | Chief Strategy Officer |
| Natasha Moshirian Wagner | Vice President of Corporate Communications |
| John Walter Hanna Jr. | President, Chief Executive Officer & Director |
| Jessica Meng | Chief Commercial Officer |
| Tina Jacobsen | Vice President of Investor Relations |
| Robert N. Woodward | Chief Scientific Officer |
Poll Results
No votes yet today — be the first to share your view!
About CareDx, Inc (NASDAQ:CDNA) Stock
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSig ... ht HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-31 18:45:00
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally, the Company's newly appointed Executive Advisor, certain stock awards as an inducement material to Mr. McNally's employment with CareDx. CareDx granted 15,822 shares of common stock restricted stock units (RSUs) to Mr. McNally. The RSU awards were made pursua.
2026-07-31 17:24:23
CareDx is helping to improve outcomes for transplant patients. The health monitor's non-invasive tests are in high demand.
CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript
2026-07-30 21:13:21
CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript
CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates
2026-07-30 18:26:07
CareDx (CDNA) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.1 per share a year ago.
CareDx Q2 Earnings Call Highlights
2026-07-30 18:06:38
CareDx NASDAQ: CDNA reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integrating the recently acquired NavDx specialty oncology platform.
CareDx Announces Second Quarter 2026 Financial Results
2026-07-30 16:01:00
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Revenue of $132 million, an increase of 52% year-over-year Testing Services revenue of $100 million, an increase of 61% year-over-year, and Testing Services volume of approximately 58,000, an increase of 17% year-o.
CareDx (CDNA) Earnings Expected to Grow: Should You Buy?
2026-07-23 11:01:31
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amova Asset Management Americas Inc. Increases Position in CareDx, Inc. $CDNA
2026-07-21 03:15:53
Amova Asset Management Americas Inc. raised its holdings in shares of CareDx, Inc. (NASDAQ: CDNA) by 2.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,475,126 shares of the company's stock after purchasing an additional 28,510 shares during the period. Amova Asset
Frequently Asked Questions
-
What is the current CareDx, Inc (CDNA) stock price?
-
CareDx, Inc(NASDAQ:CDNA) stock price is $45.5 in the last trading session. During the trading session, CDNA stock reached the peak price of $49.76 while $11.259 was the lowest point it dropped to. The percentage change in CDNA stock occurred in the recent session was --3.38% while the dollar amount for the price change in CDNA stock was -$1.59.
-
CDNA's industry and sector of operation?
-
The NASDAQ listed CDNA is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of CDNA?
-
Jeffrey A. Novack | General Counsel & Secretary
Kashif Rathore | Chief Technology Officer
Keith S. Kennedy | CFO & COO
Jing Huang | Chief Data & Artificial Intelligence Officer
Marica Grskovic | Chief Strategy Officer -
How many employees does CDNA have?
-
Number of CDNA employees currently stands at 765. CDNA operates from 8000 Marina Boulevard, Brisbane, CA 94005, US.
-
Link for CDNA official website?
-
Official Website of CDNA is: https://www.caredx.com
-
How do I contact CDNA?
-
CDNA could be contacted at phone #415 287 2300 and can also be accessed through its website. CDNA operates from 8000 Marina Boulevard, Brisbane, CA 94005, US.
-
How many shares of CDNA are traded daily?
-
The average number of CDNA shares traded daily for last 3 months was 908.85K.
-
What is the market cap of CDNA currently?
-
The market value of CDNA currently stands at $2.35B with its latest stock price at $45.5